source
- Mentari Therapeutics to go public via reverse merger with InMed, raising $290 million for migraine antibody programsMentari Therapeutics, a spinout of Paragon, announced a reverse merger with InMed Pharmaceuticals that will take the company public under the Mentari name. The deal has received board approval fro…
- Acceleron veterans and Westlake back new IPF biotech Oorja Bio with $30 million Series AEntrepreneurs who previously brought the drug Winrevair to market have launched a new biotech, Oorja Bio, to target idiopathic pulmonary fibrosis, a hard-to-treat lung disease. The company announc…